Skip Navigation

Cardiovascular Research 1999 44(3):579-587; doi:10.1016/S0008-6363(99)00239-4
© 1999 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hayek, T.
Right arrow Articles by Keidar, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayek, T.
Right arrow Articles by Keidar, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1999, European Society of Cardiology

The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice

Tony Hayeka, Judith Attiasa, Raymond Colemanb, Sergey Brodskya, Jonathan Smithc, Jan L. Breslowc and Shlomo Keidara,*

aThe Lipid Research Laboratory, Technion Faculty of Medicine, the Rappaport Institute for Research in the Medical Sciences, Haifa, Israel
bAnatomy Department, Technion, Haifa, Israel
cThe Laboratory of Biochemical Genetics and Metabolism, The Rockefeller University, New York, NY, USA

* Corresponding author. Tel.: +972-4-854-2059; fax: +972-4-854-2359 skeidar{at}rambam.health.gov.il

Objective: To investigate the possible mechanisms of the antiatherosclerotic effects of the angiotensin-converting enzyme (ACE) inhibitor, fosinopril, in apolipoprotein (apo) E deficient mice. Methods: Apo E deficient (E0) mice at the age of 8 weeks received either placebo or a high dose (25 mg/kg/d) of fosinopril supplemented in their drinking water. Results: After 12 weeks of treatment, fosinopril reduced the aortic lesion size by 70%, compared with the placebo group. At this dosage, fosinopril significantly reduced blood pressure from 93±2 mmHg before treatment to 70±2 mmHg at the end of the treatment period (P<0.005). Fosinopril also increased the resistance of the mice plasma low density lipoprotein (LDL) to CuSO4-induced oxidation, as shown by a 90% reduction in the LDL content of malondialdehyde (MDA) and also by a prolongation of the lag time required for the initiation of LDL oxidation (from 100 min in the placebo-treated mice to more than 240 min in the fosinopril-treated mice; P<0.001). In addition, fosinopril inhibited CuSO4-induced oxidation of LDL that was obtained from the aortas of the treated mice, as shown by an 18% and 37% reduction in the LDL content of lipid peroxides and hydroperoxy-cholesterol linoleate, respectively, compared with the placebo-treated mice (P<0.01). A low dosage of fosinopril (5 mg/kg/d) that was still adequate to reduce their plasma ACE activity and LDL propensity to lipid peroxidation was insufficient to lower their blood pressure. This dosage also reduced the aortic lesion size in the apo E deficient mice by 40% (P<0.01). Conclusions: The antiatherogenic effects of fosinopril in apo E deficient mice are due not only to blood pressure reduction but also to the direct inhibition of angiotensin II-dependent effects, which are probably also associated with the inhibition of LDL oxidation.

KEYWORDS Atherosclerosis; Apo E deficient mice; LDL oxidation; Angiotensin II; Blood pressure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Circ. Res.Home page
B. Ramkhelawon, J. Vilar, D. Rivas, B. Mees, R. de Crom, A. Tedgui, and S. Lehoux
Shear Stress Regulates Angiotensin Type 1 Receptor Expression in Endothelial Cells
Circ. Res., October 23, 2009; 105(9): 869 - 875.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Kappert, O. Tsuprykov, J. Kaufmann, J. Fritzsche, I. Ott, M. Goebel, I. N. Bahr, P.-L. Hassle, R. Gust, E. Fleck, et al.
Chronic Treatment With Losartan Results in Sufficient Serum Levels of the Metabolite EXP3179 for PPAR{gamma} Activation
Hypertension, October 1, 2009; 54(4): 738 - 743.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Kvakan, M. Kleinewietfeld, F. Qadri, J.-K. Park, R. Fischer, I. Schwarz, H.-P. Rahn, R. Plehm, M. Wellner, S. Elitok, et al.
Regulatory T Cells Ameliorate Angiotensin II-Induced Cardiac Damage
Circulation, June 9, 2009; 119(22): 2904 - 2912.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. K. Koh, P. C. Oh, and M. J. Quon
Does reversal of oxidative stress and inflammation provide vascular protection?
Cardiovasc Res, March 1, 2009; 81(4): 649 - 659.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
I. Imayama, T. Ichiki, D. Patton, K. Inanaga, R. Miyazaki, H. Ohtsubo, Q. Tian, K. Yano, and K. Sunagawa
Liver X Receptor Activator Downregulates Angiotensin II Type 1 Receptor Expression Through Dephosphorylation of Sp1
Hypertension, June 1, 2008; 51(6): 1631 - 1636.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Kojima, A. Kawakami, T. Takei, K. Nitta, and M. Yoshida
Angiotensin-Converting Enzyme Inhibitor Attenuates Monocyte Adhesion to Vascular Endothelium through Modulation of Intracellular Zinc
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 855 - 860.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen
Angiotensin-Converting Enzyme and Vascular Remodeling
Circ. Res., August 31, 2007; 101(5): 441 - 454.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1706 - 1721.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
E. Suganuma, V. R. Babaev, M. Motojima, Y. Zuo, N. Ayabe, A. B. Fogo, I. Ichikawa, M. F. Linton, S. Fazio, and V. Kon
Angiotensin Inhibition Decreases Progression of Advanced Atherosclerosis and Stabilizes Established Atherosclerotic Plaques
J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2311 - 2319.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Bro, C. J. Binder, J. L. Witztum, K. Olgaard, and L. B. Nielsen
Inhibition of the Renin-Angiotensin System Abolishes the Proatherogenic Effect of Uremia in Apolipoprotein E-Deficient Mice
Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1080 - 1086.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
L. Yvan-Charvet, P. Even, N. Lamande, P. Ferre, and A. Quignard-Boulange
Prevention of Adipose Tissue Depletion during Food Deprivation in Angiotensin Type 2 Receptor-Deficient Mice
Endocrinology, November 1, 2006; 147(11): 5078 - 5086.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
V. L. Sales, G. K. Sukhova, M. A. Lopez-Ilasaca, P. Libby, V. J. Dzau, and R. E. Pratt
Angiotensin Type 2 Receptor Is Expressed in Murine Atherosclerotic Lesions and Modulates Lesion Evolution
Circulation, November 22, 2005; 112(21): 3328 - 3336.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. K. Koh, M. J. Quon, S. H. Han, W.-J. Chung, J. Y. Ahn, Y.-H. Seo, M. H. Kang, T. H. Ahn, I. S. Choi, and E. K. Shin
Additive Beneficial Effects of Losartan Combined With Simvastatin in the Treatment of Hypercholesterolemic, Hypertensive Patients
Circulation, December 14, 2004; 110(24): 3687 - 3692.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Wassmann, T. Czech, M. van Eickels, I. Fleming, M. Bohm, and G. Nickenig
Inhibition of Diet-Induced Atherosclerosis and Endothelial Dysfunction in Apolipoprotein E/Angiotensin II Type 1A Receptor Double-Knockout Mice
Circulation, November 9, 2004; 110(19): 3062 - 3067.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Rosenhek, F. Rader, N. Loho, H. Gabriel, M. Heger, U. Klaar, M. Schemper, T. Binder, G. Maurer, and H. Baumgartner
Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis
Circulation, September 7, 2004; 110(10): 1291 - 1295.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. K. Koh, J. W. Son, J. Y. Ahn, D. S. Kim, D. K. Jin, H. S. Kim, S. H. Han, Y.-H. Seo, W.-J. Chung, W. C. Kang, et al.
Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic Patients
Hypertension, August 1, 2004; 44(2): 180 - 185.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Hayek, E. Pavlotzky, S. Hamoud, R. Coleman, S. Keidar, M. Aviram, and M. Kaplan
Tissue Angiotensin-Converting-Enzyme (ACE) Deficiency Leads to a Reduction in Oxidative Stress and in Atherosclerosis: Studies in ACE-Knockout Mice Type 2
Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 2090 - 2096.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. K. Koh, J. Y. Ahn, S. H. Han, D. S. Kim, D. K. Jin, H. S. Kim, M.-S. Shin, T. H. Ahn, I. S. Choi, and E. K. Shin
Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients
J. Am. Coll. Cardiol., September 3, 2003; 42(5): 905 - 910.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
B. M. Singh and J. L. Mehta
Interactions Between the Renin-Angiotensin System and Dyslipidemia: Relevance in the Therapy of Hypertension and Coronary Heart Disease
Arch Intern Med, June 9, 2003; 163(11): 1296 - 1304.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. R. Brasier, A. Recinos III, and M. S. Eledrisi
Vascular Inflammation and the Renin-Angiotensin System
Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1257 - 1266.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Y. Imai, T. Shindo, K. Maemura, M. Sata, Y. Saito, Y. Kurihara, M. Akishita, J. Osuga, S. Ishibashi, K. Tobe, et al.
Resistance to Neointimal Hyperplasia and Fatty Streak Formation in Mice With Adrenomedullin Overexpression
Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1310 - 1315.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Kramer, J. Sunkomat, J. Witte, M. Luchtefeld, M. Walden, B. Schmidt, R. H. Boger, W.-G. Forssmann, H. Drexler, and B. Schieffer
Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179
Circ. Res., April 19, 2002; 90(7): 770 - 776.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
S. Keidar, R. Heinrich, M. Kaplan, and M. Aviram
Oxidative stress increases the expression of the angiotensin-II receptor type 1 in mouse peritoneal macrophages
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 24 - 30.
[Abstract] [PDF]


Home page
CirculationHome page
J. Chen, P. J. Kuhlencordt, J. Astern, R. Gyurko, and P. L. Huang
Hypertension Does Not Account for the Accelerated Atherosclerosis and Development of Aneurysms in Male Apolipoprotein E/Endothelial Nitric Oxide Synthase Double Knockout Mice
Circulation, November 13, 2001; 104(20): 2391 - 2394.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Keidar, R. Heinrich, M. Kaplan, T. Hayek, and M. Aviram
Angiotensin II Administration to Atherosclerotic Mice Increases Macrophage Uptake of Oxidized LDL: A Possible Role for Interleukin-6
Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1464 - 1469.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. H. Selzman, S. A. Miller, and A. H. Harken
Therapeutic implications of inflammation in atherosclerotic cardiovascular disease
Ann. Thorac. Surg., June 1, 2001; 71(6): 2066 - 2074.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Wassmann, U. Laufs, A. T. Baumer, K. Muller, K. Ahlbory, W. Linz, G. Itter, R. Rosen, M. Bohm, and G. Nickenig
HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species
Hypertension, June 1, 2001; 37(6): 1450 - 1457.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
U. Kintscher, S. Wakino, S. Kim, E. Fleck, W. A. Hsueh, and R. E. Law
Angiotensin II Induces Migration and Pyk2/Paxillin Phosphorylation of Human Monocytes
Hypertension, February 1, 2001; 37(2): 587 - 593.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
M. d. Gasparo, P. Hess, B. Nuesslein-Hildesheim, P. Bruneval, and J.-P. Clozel
Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 151 - 158.
[Abstract] [PDF]


Home page
Circ. Res.Home page
C. Kramer, J. Sunkomat, J. Witte, M. Luchtefeld, M. Walden, B. Schmidt, R. H. Boger, W.-G. Forssmann, H. Drexler, and B. Schieffer
Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179
Circ. Res., April 19, 2002; 90(7): 770 - 776.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.